Comparative Pharmacology
Head-to-head clinical analysis: PROLIXIN ENANTHATE versus QUIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PROLIXIN ENANTHATE versus QUIDE.
PROLIXIN ENANTHATE vs QUIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Fluphenazine (the active entity of PROLIXIN ENANTHATE) is a phenothiazine antipsychotic that blocks postsynaptic dopamine D1 and D2 receptors in the mesolimbic and mesocortical pathways. It also exhibits alpha-adrenergic blocking and anticholinergic effects.
Quetiapine acts as an antagonist at multiple neurotransmitter receptors in the brain, including serotonin 5-HT2A, dopamine D2, histamine H1, and adrenergic α1 receptors. It also has partial agonist activity at serotonin 5-HT1A receptors. This atypical antipsychotic action is mediated primarily through 5-HT2A and D2 antagonism.
12.5-50 mg intramuscularly every 1-3 weeks. Initial dose: 2.5-12.5 mg IM as a test dose; gradual titration based on response and tolerability.
5 mg orally once daily, with or without food.
None Documented
None Documented
Terminal elimination half-life approximately 11-15 days due to slow release from intramuscular depot; requires monitoring for prolonged effects after discontinuation
2-4 hours (prolonged in renal impairment, requiring dose adjustment)
Primarily renal (30-40% as metabolites, <1% unchanged) and biliary/fecal (15-20%)
Primarily renal (80% as unchanged drug); minor fecal (20%)
Category C
Category C
Antipsychotic
Antipsychotic